GlassScriptPhysician profile
Janette E Stallings
NPI 1871092353
$7,488.38
in general payments reported to CMS, 2019-2025
23 companies · $1,574 in 2025
The $1,574 reported for 2025 was more than what 89% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $613 · 2022: $1,791 · 2023: $1,648 · 2024: $1,862 · 2025: $1,574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,072 · Education: $11.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,071.85 |
| Education | $11.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,238.40 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,176.09 | 2022-2025 | Caplyta |
| Abbvie INC. | $855.60 | 2021-2025 | |
| Harmony Biosciences LLC | $505.82 | 2022-2025 | Wakix |
| Vanda Pharmaceuticals INC. | $486.57 | 2023-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $478.32 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $369.81 | 2022-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $362.05 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $354.90 | 2022-2025 | Qelbree |
| Alkermes, INC. | $295.94 | 2022-2023 | Lybalvi, Aristada |
| Lundbeck LLC | $230.86 | 2021-2025 | Rexulti |
| Bausch Health US, LLC | $230.15 | 2022-2023 | Wellbutrin, Aplenzin |
| Neos Therapeutics, LP | $195.10 | 2021-2025 | Adzenys Xr-Odt, Exxua |
| Idorsia Pharmaceuticals US INC | $194.55 | 2022-2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $174.09 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $98.32 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $66.02 | 2025 | Cobenfy |
| Novo Nordisk INC | $46.66 | 2024-2025 | Wegovy |
| Ironshore Pharmaceuticals INC. | $44.41 | 2023-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $41.40 | 2025 | Jornay Pm |
| Tris Pharma INC | $15.81 | 2024 | Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $13.97 | 2023 | Austedo |
| Noven Therapeutics, LLC | $13.54 | 2024 | Secuado, Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janette Stallings listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.